Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, T-cell and B-cell Immunology, and CAR-T cell therapy research.
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.